Guidant FUTURE Results Show No In-Stent Restenosis At Six Months
This article was originally published in The Gray Sheet
Executive Summary
Late lumen loss rates observed in Guidant's FUTURE I/II everolimus-eluting stent trials are consistent with J&J/Cordis' SIRIUS data, according to investigator Eberhard Grube, MD, Heart Center Sieburg, Germany
You may also be interested in...
Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes
Guidant acknowledges that its initial drug-eluting stent may have to be a cobalt-chromium, durable-polymer stent if design changes to the bioabsorbable-polymer Champion require renewed preclinical or clinical testing
Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes
Guidant acknowledges that its initial drug-eluting stent may have to be a cobalt-chromium, durable-polymer stent if design changes to the bioabsorbable-polymer Champion require renewed preclinical or clinical testing
Guidant Chief Exec Calls Exit “Perfect Timing”; Neels Rises To COO
Guidant's management reshuffle coincides with a shift in operational focus toward manufacturing and marketing a drug-eluting stent of its own